



MEDIPURE FILES PROVISIONAL PATENT FOR ANXIETY TREATMENT

June 16, 2015 – Vancouver, BC – Medipure Holdings Inc. [CSE:MDH] is pleased to announce that its subsidiary, Medipure Pharmaceuticals Inc. (“Medipure,” or the “Company”), has filed a provisional patent application with the United States Patent and Trademark Office (“USPTO”) for a therapeutic formulation that treats anxiety through the combination of cannabinoids, which is the base of Medipure’s MP-20X product line.

“We are very pleased to formally file this provisional patent for anxiety treatment,” stated Boris Weiss, Medipure’s Chief Executive Officer. “This filing is evidence of the considerable potential of our research and development efforts, and represents the next step in our plan to develop a considerable portfolio of intellectual property. There is currently no cannabinoid-based prescription pharmaceutical available for the treatment of anxiety. We are excited to break new ground in this regard, with a formulation that may be administered either transmucosally or orally. Many existing anti-anxiety medications, also known as anxiolytic products, can result in undesired side effects. Our objective is to develop more effective options for both doctors and patients - pharmaceutical medications that will not only be better tolerated by people with anxiety and other mood disorders, but also mitigate issues related to drug dependency that are often witnessed in currently available prescription drugs.”

A provisional patent application is a legal document that establishes an early priority date for the benefit of claiming "first to file" status against other companies or individuals that may want to file for a patent with similar claims after the filing date of Medipure’s provisional application.

About Medipure Holdings Inc.

Medipure Holdings Inc. is a biopharmaceutical company focused on developing and marketing novel cannabinoid-based prescription medicines through its subsidiary, Medipure Pharmaceuticals Inc. Medipure is creating a network of strategic partnerships with extensive experience in developing cannabinoids, medicines containing controlled substances, as well as plant-based bioactive molecules into prescription pharmaceutical products. Medipure will bring novel prescription medicines to market, providing patients with serious conditions valuable solutions that make a real difference to quality of life. Medipure will also seek to maximize the value of developed products through rapid, cost-effective product development, addressing market needs, and establishing further strategic partnerships as the company matures. The Medipure Cannabinoid Research Centre will perform pharmaceutical research, licensed through the *Narcotics Control Regulations* and *Controlled Drugs and Substances Act*, and will be

collaborating with appropriately licensed labs in academic and clinical settings in order to perform its cannabinoid R&D. Medipure has applied to Health Canada for a license to produce and distribute medical marijuana under the Marihuana for Medical Purposes Regulations. The company has not yet received such a license and there is no guarantee that such a license will be granted to Medipure by Health Canada. However, the pharmaceutical research and development program at Medipure exists independently of a license for the production of marijuana.

For more information, please contact:

Nathan Sellyn
Investor Relations
nsellyn@medipurepharma.com

Boris Weiss
Chief Executive Officer
boris@medipurepharma.com

Forward-Looking Statements

Information in this press release that is not current or historical factual information may constitute forward-looking information, including future-oriented financial information and financial outlooks, within the meaning of securities laws. This information is based on certain assumptions regarding expected growth, results of operations, performance, and business prospects and opportunities. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the companies cannot provide any assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release and the companies disclaim any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.